Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
基本信息
- 批准号:7563228
- 负责人:
- 金额:$ 13.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-02-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Megakaryocytic LeukemiasAddressAffectAllelesCellsChildChimeric ProteinsChromosomal translocationComplementDataDevelopmentDiseaseDown SyndromeFibrinogenFunctional disorderGene ComponentsGene DosageGene ExpressionGenesHematopoiesisHematopoieticHumanIn VitroInfantKnock-in MouseKnock-outKnockout MiceMediatingMegakaryocyte ProliferationMegakaryocytesMegakaryocytopoiesesModelingMolecularMusMutatePathogenesisPathway interactionsPatternPhenotypePhysiologicalPhysiologyPreparationPropertyProteinsReagentRegulationRoleTherapeutic Interventionin vivoinsightleukemialeukemogenesismouse modelnoveloverexpressionpromoterstoichiometrytranscription factor
项目摘要
DESCRIPTION (provided by applicant): The majority of infant acute megakaryocytic leukemias (AMKL) in non-Down Syndrome children have a unique chromosomal translocation, t(1;22). This translocation fuses two novel genes believed to be transcription factors, OTT (a.k.a. RBM15) and MAL (a.k.a. MKL1/MRTF-A/BSAC), and results in the expression of a chimeric protein. Homologous structural motifs within the fusion have been identified in proteins known to be involved in differentiation, proliferation and leukemogenesis. To elucidate the pathophysiology induced by the OTT-MAL fusion protein, mice have been generated using a knock-in approach to express OTT-MAL from the OTT locus. By expressing the fusion protein from the endogenous OTT promoter, the stoichiometry and expression pattern of OTT-MAL found in the human leukemia should be reproduced. Evolving data suggests subtle differences in gene dosage and regulation have a critical impact on leukemogenesis and normal megakaryopoiesis.
Identification of the pathways by which OTT-MAL may induce leukemogenesis will require a more comprehensive understanding of the component genes, OTT and MAL as their hematopoietic roles are unknown. Deletion of OTT or MAL in mice will provide an invaluable reagent in defining the pathways dysregulated by OTT-MAL in terms of gene expression and physiology. The role of OTT-MAL in t(1;22) AMKL will be investigated using routine models to address the following questions:
Specific Aim 1. What are the consequences of OTT-MAL expression in mice?
Specific Aim 2. What is the in vivo physiologic role of OTT and which pathways of endogenous OTT are utilized by the OTT-MAL fusion protein?
Specific Aim 3. What role does MAL function have in normal physiology and in OTT-MAL-mediated dysregulation?
The establishment and analysis of a murine model of t(1;22) AMKL will provide new opportunities for the study of pathogenesis in AMKL, potential therapeutic interventions and fundamental insight into megakaryocyte development.
描述(由申请人提供):大多数非唐氏综合征儿童中的婴儿急性巨核细胞白血病(AMKL)具有独特的染色体易位t(1;22)。这种易位融合了两个新的基因,据信是转录因子,OTT(又名OTT)。RBM15)和MAL(a.k.a. MKL 1/MRTF-A/BSAC),并导致嵌合蛋白的表达。在已知参与分化、增殖和白血病发生的蛋白质中已经鉴定出融合内的同源结构基序。为了阐明由OTT-MAL融合蛋白诱导的病理生理学,使用敲入方法从OTT基因座表达OTT-MAL来产生小鼠。通过表达来自内源性OTT启动子的融合蛋白,应当再现在人白血病中发现的OTT-MAL的化学计量和表达模式。不断发展的数据表明,基因剂量和调控的细微差异对白血病发生和正常的巨核细胞生成有重要影响。
鉴定OTT-MAL可能诱导白血病发生的途径需要更全面地了解组成基因OTT和MAL,因为它们的造血作用尚不清楚。小鼠中OTT或MAL的缺失将为确定OTT-MAL在基因表达和生理学方面失调的途径提供宝贵的试剂。将使用常规模型研究OTT-MAL在t(1;22)AMKL中的作用,以解决以下问题:
具体目标1. OTT-MAL在小鼠中表达的后果是什么?
具体目标2。 OTT在体内的生理作用是什么,OTT-MAL融合蛋白利用内源性OTT的哪些途径?
具体目标3。 MAL功能在正常生理和OTT-MAL介导的失调中起什么作用?
t(1;22)AMKL小鼠模型的建立和分析将为AMKL发病机制的研究、潜在的治疗干预和巨核细胞发育的基础性认识提供新的机会。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Glen D Raffel其他文献
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
- DOI:
10.1182/blood-2023-190037 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
John DiPersio;Brenda W Cooper;Hyung C Suh;Divya Koura;Lea Bernard;Nirali N. Shah;Roland B. Walter;Miguel-Angel Perales;Markus Mapara;Roni Tamari;Michael R. Loken;Kyle Breitschwerdt;Sritama Nath;Glen D Raffel;Guenther Koehne - 通讯作者:
Guenther Koehne
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
- DOI:
10.1182/blood-2024-205641 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
John F. DiPersio;Guenther Koehne;Nirali N. Shah;Lea Bernard;Hyung C Suh;Divya Koura;Miguel Angel Perales;Roni Tamari;Muhammad Umair Mushtaq;Joseph E. Maakaron;Michael R. Loken;Darren A Stanizzi;Melissa M. Lee-Sundlov;Sanjana Thosar;Sharon L Hyzy;Glen D Raffel;Brenda W Cooper - 通讯作者:
Brenda W Cooper
Glen D Raffel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Glen D Raffel', 18)}}的其他基金
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
10163910 - 财政年份:2020
- 资助金额:
$ 13.44万 - 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
10409804 - 财政年份:2020
- 资助金额:
$ 13.44万 - 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
10601077 - 财政年份:2020
- 资助金额:
$ 13.44万 - 项目类别:
Hematopoietic regulation through Ott1-dependent alternative splicing
通过 Ott1 依赖的选择性剪接进行造血调节
- 批准号:
8708200 - 财政年份:2013
- 资助金额:
$ 13.44万 - 项目类别:
Hematopoietic regulation through Ott1-dependent alternative splicing
通过 Ott1 依赖的选择性剪接进行造血调节
- 批准号:
8579535 - 财政年份:2013
- 资助金额:
$ 13.44万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
7336370 - 财政年份:2005
- 资助金额:
$ 13.44万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
7176783 - 财政年份:2005
- 资助金额:
$ 13.44万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia.
婴儿急性巨核细胞白血病小鼠模型。
- 批准号:
7008162 - 财政年份:2005
- 资助金额:
$ 13.44万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
6851221 - 财政年份:2005
- 资助金额:
$ 13.44万 - 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
9891829 - 财政年份:
- 资助金额:
$ 13.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 13.44万 - 项目类别:
Research Grant